SGLT2 Inhibitors Treatment Market Outlook:
SGLT2 Inhibitors Treatment Market size was valued at USD 20.7 billion in 2025 and is projected to reach USD 40.3 billion by the end of 2035, rising at a CAGR of 7.7% during the forecast period, from, 2026-2035. In 2026, the industry size of SGLT2 Inhibitors Treatment is estimated at USD 22.2 billion.
The rapidly escalating patient pool affected by type 2 diabetes, chronic kidney disease (CKD), and cardiovascular diseases is the primary fueling factor behind the robust growth of the worldwide market. This can be testified by the report from the International Diabetes Federation published in 2024, which states that around 589 million adults aged between 20 to 79 are living with diabetes across all nations, which means one out of every 9 people. It further underscored that the number is expected to double by the end of 2050, reflecting the huge necessity for SGLT2 inhibitors. Furthermore, this led to USD 1 trillion in health expenditure, marking a 338% increase over the past two decades, hence positively impacting market growth.
Furthermore, the regulatory and administrative support for this merchandise has been constantly growing, which attracts a larger pool of service providers to operate in this field. Guidelines from authorities such as the American Diabetes Association and the European Society of Cardiology currently recommend SGLT2 inhibitors for a broader patient population beyond type 2 diabetes alone. Therefore, as per an article by the joint consensus report from KDIGO and ADA published in November 2022, SGLT2 inhibitors with proven kidney benefits are recommended for most patients with type 2 diabetes and chronic kidney disease, especially those with an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73 m² or more.
